Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
RECRUITING
NCT06963021
PHASE3

NBI-1065845-MDD3026: Study to Assess the Efficacy and Safety of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)

Sponsor: Neurocrine Biosciences

View on ClinicalTrials.gov

Summary

The study will evaluate the efficacy of NBI-1065845 compared with placebo as an adjunctive treatment in participants with MDD on improving symptoms of depression.

Official title: A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of NBI-1065845 as Adjunctive Treatment in Subjects With Major Depressive Disorder (MDD)

Key Details

Gender

All

Age Range

18 Years - Any

Study Type

INTERVENTIONAL

Enrollment

200

Start Date

2025-05-30

Completion Date

2027-07

Last Updated

2025-12-22

Healthy Volunteers

No

Interventions

DRUG

NBI-1065845

NBI-1065845 tablets

DRUG

Placebo

Matching placebo tablets

Locations (16)

Neurocrine Clinical Site

Los Angeles, California, United States

Neurocrine Clinical Site

Aurora, Colorado, United States

Neurocrine Clinical Site

Cromwell, Connecticut, United States

Neurocrine Clinical Site

Farmington, Connecticut, United States

Neurocrine Clinical Site

Maitland, Florida, United States

Neurocrine Clinical Site

Tampa, Florida, United States

Neurocrine Clinical Site

Gaithersburg, Maryland, United States

Neurocrine Clinical Site

Cedarhurst, New York, United States

Neurocrine Clinical Site

New York, New York, United States

Neurocrine Clincial Site

New York, New York, United States

Neurocrine Clinical Site

Alken, Belgium

Neurocrine Clinical Site

Mechelen, Belgium

Neurocrine Clinical Site

Oulu, Finland

Neurocrine Clinical Site

Jelgava, Latvia

Neurocrine Clinical Site

Liepāja, Latvia

Neurocrine Clinical Site

Sigulda, Latvia